Home
Resources
Publications
Ezatiostat Hydrochloride for the Treatment of Myelodysplastic Syndromes

Ezatiostat Hydrochloride for the Treatment of Myelodysplastic Syndromes

Daruka Mahadevan, Gregory Ryan Sutton

Expert Opin Investig Drugs. 2015 May;24(5):725-33.

PMID: 25724698

Abstract:

Introduction:
Myelodysplastic syndromes (MDSs) are associated with significant morbidity due to ineffective hematopoiesis. Given the limited number of drugs approved by the FDA, there is a need for new therapeutic options. Ezatiostat is a novel agent targeting oxidative stress via inhibition of glutathione S-transferase 1.
Areas covered:
Herein, the authors summarize the standard of care in order to build the framework for therapeutic advancements. The purpose of this paper is to review the body of preclinical and clinical research literature on the investigational agent ezatiostat hydrochloride (TLK199) for the treatment of MDSs. The article includes details of the pathophysiology, pharmacology, toxicity and efficacy of ezatiostat hydrochloride from controlled studies in patients with myelodysplasia.
Expert opinion:
MDS clonal heterogeneity and clonal architecture complexity has presented a significant technical challenge in developing effective therapies. Ezatiostat offers a unique and specific mechanism to improve the transfusion burden associated with myelodysplasia. Since it is tolerable as a monotherapy, combining ezatiostat with agents such as lenalidomide may have the most potential benefit.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP168682539	Ezatiostat		168682-53-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: